Sbi Pharmaceuticals Co., Ltd.

Nippon Telegraph and Telephone Corporation

The University of Tokyo

Tokyo Institute of Technology

Cosmo Oil Co., Ltd.

Kochi University

Ando Electric Company

Other

Mitsubishi Denki Kabushiki Kaisha

Ihi Corporation

Tohoku University

Nihon University

Kumamoto University

Yamagata University

Osaka City University

Tohru Tanaka

Motowo Nakajima

Kiwamu Takahashi

Fuminori Abe

Masahiro Ishizuka

Hidenori Ito

Ko Rii

Satofumi Kawata

Takuya Ishii

Yasuko Maruo

Naomi Haga

Shigeo Ogawa

Keiji Inoue

Seizou Sakata

Takeo Kohda

Hideki Okada

Kiyoshi Kita

Setsuko Miyanari

Katsushi Inoue

Shun-ichiro Ogura

Mutsuo Furihata

Taro Shuin

Masayuki Tsuda

Hideo Fukuhara

Masao Kondo

Atsushi Sakurai

Takeshi Suzuki

Takeshi Nomura

Sotsuo Miyoshi

Jun Abe

Kouji Matsushima

Naomichi Omori

Toshihiko Miyake

Hiroyuki Ishikawa

Takashi Ohyama

Takaaki Abe

Tadashi Mitsui

Hiroshi Kido

Seiji Nishikawa

Satoshi Ueha

Takayoshi Hayashi

Shiro Matsumoto

Keitaro Watanabe

Masaaki Wachi

Naohisa Tachiya

Tetsuya Yoneda

Shinichi Kawasaki

Masumi Takahashi

Mai Higo

Yasuhisa Kitajima

Naomi Aiba

Urara Ota

Toshiyuki Ozawa

Hitoshi Nakagawa

Shogo Shimizu

Takahiro Masubuchi

Yoshihiko Hirao

Hideya Yuasa

Katushi Inoue

Mitsuru Inamura

Kyoko Tsuchiya

Toshihiro Kobori

Junkoh Yamamoto

Urara Oto

Hidenori Itoh

Atsuko Kamiya

Kuniyuki Morimoto

Tsutomu Numata

Mariko Shibuya

Kosaku Kinoshita

Shunsuke Yoshida

Motoaki Saito

Katsuhisa Tanjoh

Akihiro Noda

Junji Chida

Kazuhiko Yamane

Takato Yoshida

Shigeru Nishizawa

Shigeharu Sato

Osamu Nakajima

Taku Chibazakura

Takahira Kuno

Toshihiko Kuroiwa

Yoshinaga Kajimoto

Kazuya Iwai

Shimizu Shogo

Takaya Suzuki

[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.

Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same

A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.

Method of removing pluripotent cells from culture

The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.

Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor

Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.

Prophylactic or therapeutic agent for hyperaciive bladder

The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.

Agent for preventing and/or treating veisalgia

It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein Rrepresents a hydrogen atom or an acyl group, and Rrepresents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg. 

Agent for improving normal development rate of fertilized eggs

The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

Enhancer of survival of transplanted organ

An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein Rrepresents a hydrogen atom or an acyl group; and Rrepresents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).

Prophylactic and/or therapeutic agent for radiation damage

It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.

Method for detection of urothelial cancer

It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 &#x3bc;m to 2.5 &#x3bc;m; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group.

Photodynamic therapy or diagnostic agent, using infrared-spectrum light

A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I):R&#x2014;NHCHCOCHCHCOOR&#x2003;&#x2003;(I)wherein Rrepresents a hydrogen atom or an acyl group, and Rrepresents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Treatment agent and/or prophylactic agent for side effects of cancer drugs

The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Medicinal composition for promoting synthesis of protoporphyrin IX

Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.

Therapeutic agent for allergic rhinitis

A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.

Anemia of cancer improving/prophylactic agent

Growing community of inventors

Tokyo, Japan

Tohru Tanaka